Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.

Alimentary pharmacology & therapeutics - 1 Aug 2024

Bridi Lana, Agrawal Saaket, Tesfai Kaleb, Madamba Egbert, Bettencourt Ricki, Richards Lisa M, Khera Amit V, Loomba Rohit, Ajmera Veeral

Abstract excerpt

BACKGROUND: Genetic factors contribute to the risk and severity of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the utility of genetic testing in risk stratification remains poorly characterised. AIMS: To examine the influence of genetic risk on advanced fibrosis and cirrhosis in patients with type 2 diabetes mellitus (T2DM) and the utility of a polygenic risk score (PRS) in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 17-Hydroxysteroid Dehydrogenases
Share to Acyltransferases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to alpha 1-Antitrypsin

Share to Elasticity Imaging Techniques

Share to Lipase

Share to Liver Cirrhosis

Share to Non-alcoholic Fatty Liver Disease

Share to Phospholipases A2, Calcium-Independent

Source

Open in PubMed Open full text

Identifiers

PMID: 38825972
DOI: 10.1111/apt.18099
PMCID: PMC11236495

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.PMID 38825972Read ↗

Early Insights from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: An Observational Study on Polygenic Risk and Liver BiomarkersSemantic proximity Read ↗

High inherited risk predicts age-associated increases in fibrosis in patients with MASLD.Semantic proximity Read ↗

A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis ScoresSemantic proximity Read ↗

Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.Semantic proximity Read ↗

Monogenic and Polygenic Risk in Common Liver Diseases: Implications for Clinical Care.Semantic proximity Read ↗

Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.Semantic proximity Read ↗

The impact of genetic risk on liver fibrosis in non‐alcoholic fatty liver disease as assessed by magnetic resonance elastographySemantic proximity Read ↗

Genetic modulators of metabolic dysfunction-associated steatotic liver disease (MASLD) and their epistatic interactions: from in vitro and animal models to clinical outcomes.Semantic proximity Read ↗

Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Semantic proximity Read ↗

Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.Semantic proximity Read ↗

Integrating PNPLA3 into clinical risk prediction.Semantic proximity Read ↗

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.